Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Phathom Pharmaceuticals, Inc. Director's Dealing 2025

May 21, 2025

32407_dirs_2025-05-21_c5ab4d64-b222-4b93-a56c-807b53f84479.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2025-05-19

Reporting Person: Breedlove Robert Charles (N/A)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2025-05-19 Stock Option (Right to Buy) $4.39 A 33000 Acquired 2035-05-18 Common Stock (33000) Direct

Footnotes

F1: The stock option will vest with respect to 25% of the shares of common stock on May 19, 2026, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the Reporting Person's continuous service to the Issuer on the applicable vesting dates.